Advanced Micro Devices, Inc. (NASDAQ:AMD) stock has reached a 52-week low, dipping to $114.41, as investors navigate a challenging market environment. According to InvestingPro data, the company ...

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and ...

The deal is structured as a private investment in a public equity and includes an equity stake in Absci. AMD didn’t disclose the amount of its stake. AMD, which is based in Santa Clara ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for ...

Absci Corporation has announced a strategic partnership with AMD to utilize AMD Instinct™ accelerators and ROCm™ software for advancing AI-driven drug discovery, specifically in de novo ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct ...

AMD collaborates with Absci for AI drug discovery advancements. AMD makes a $20 million investment to boost drug research. The partnership will leverage AMD Instinct accelerators and ROCm software ...

(RTTNews) - Absci Corporation (ABSI), a Washington-based biotechnology company, Wednesday has announced a strategic collaboration with AMD to deploy AMD Instinct accelerators and ROCm software to ...

The partnership will leverage AMD Instinct accelerators and ROCm software to support Absci’s advanced de novo antibody design models. The deal also includes a $20 million private investment in ...

$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software “We are proud ...